This month, ELZA celebrates the publication of our latest corneal cross-linking (CXL) review in Progress in Retinal and Eye Research, with several of our team members having authored this paper. This journal, recognized as one of the most prestigious in ophthalmology, is a leading resource for groundbreaking advances in the field. Our comprehensive review explores the science, evolution, and clinical applications of CXL—a transformative procedure that has revolutionized the treatment of keratoconus and other corneal conditions.
A Comprehensive CXL Review
Our review provides an in-depth examination of the history and advancements in CXL. From its initial use in keratoconus management to its current applications in infectious keratitis, corneal ectasias, and beyond, this article highlights the versatility and innovation behind this procedure. Key topics include:
- Epi-off and Epi-on Techniques: Traditional and minimally invasive methods tailored for diverse patient needs.
- Accelerated CXL Protocols: Techniques that significantly reduce procedure time while maintaining effectiveness.
- Customized Treatments: Innovations like ELZA-PACE, developed at the ELZA Institute, that reshape and stabilize the cornea without tissue removal.
- Adaptations for Thin Corneas: Protocols such as the ELZA-sub400 technique for safely treating corneas thinner than 400 micrometers.
This CXL review is a valuable resource for ophthalmologists and researchers, providing practical insights into optimizing patient outcomes and exploring the latest advances in this field.
A Resource for Surgeons and Researchers
The review synthesizes decades of research into a single, accessible resource. It explores both the fundamental science—such as corneal biomechanics and photochemistry—and the practical applications that clinicians can adopt to improve patient care. It is designed to be a reference point for understanding CXL advancements and their clinical implications.
Why This Publication Matters
Publishing in Progress in Retinal and Eye Research is a significant achievement. This journal has the highest impact factor in ophthalmology and is known for setting the benchmark for excellence in the field.
This recognition highlights the ELZA Institute’s leadership in corneal research and innovation, reinforcing our commitment to advancing patient care and contributing to the global understanding of transformative treatments like CXL.
Access the Article Now
We invite you to explore this review and gain insights into the science and future of corneal cross-linking. The article is free to read until February 18th.
For more information about our innovative keratoconus treatments and advanced CXL protocols, visit our Keratoconus Treatment page.
